Announced details
DDAIF has been adopted by multiple major pharmaceutical companies (company names and number of deployments are not disclosed)
FRONTEO will participate in the seminar hosted by the company as a speaker and panel discussion participant. Capital and personnel relationships are not disclosed.
The company that hosts the Medical Industry Growth Strategy Seminar. Other company details are not disclosed.
A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
International House of Japan, 5-11-16 Roppongi, Minato-ku, Tokyo
Participation fee: ¥23,000 for in-person attendance / ¥16,000 online
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Equation-driven AI “KIBIT (Kibit)”, Drug Discovery AI Factory（DDAIF） |
| Counterparty | 株式会社イノベーション・フォー・ヘルスケア (Medical Industry Growth Strategy Seminar Secretariat) |
| Counterparty overview | The company that hosts the Medical Industry Growth Strategy Seminar. Other company details are not disclosed. |
| Relationship with the Company | FRONTEO will participate in the seminar hosted by the company as a speaker and panel discussion participant. Capital and personnel relationships are not disclosed. |
| Offering price | Participation fee: ¥23,000 for in-person attendance / ¥16,000 online |
| Launch date | 15 July 2026 (scheduled; seminar date) |
| Applicable area | AI drug discovery, Drug Development, Disease-related gene network analysis, Hypothesis development regarding candidate target molecules, Healthcare DX, AI and data strategy |
| Registration number and expiry date | A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | International House of Japan, 5-11-16 Roppongi, Minato-ku, Tokyo |
| Location scale | Capacity: 500 (250 in-person / 250 online) |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies (company names and number of deployments are not disclosed) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To introduce and discuss the use of AI and the drug discovery ecosystem for strengthening Japan’s drug discovery capabilities with leaders from industry, academia and government in the medical industry.